Cadrenal Therapeutics Inc. – Filings and Transcripts

NASDAQ: CVKD
Share price (6/26/26): $3.05
Market cap (6/26/26): $9.389 million

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 03/31/26 Q1

ended 12/31/25 FY 2025

ended 09/30/25 Q3

ended 06/30/25 Q2

ended 03/31/25 Q1

Prospectuses and Registrations Filter

Prospectus supplement

Shelf registration

Exempt offering of securities

Prospectus supplement for primary offering

Prospectus supplement

Ownership Filter

News Filter

To File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease

Change in Directors, Officers or Compensation, Financial Statements or Exhibits

Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-Of-Phase 2 Meeting With FDA

Announces End-Of-Phase 2 Meeting With the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia

Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Financial Statements or Exhibits

Proxies Filter

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Definitive proxy

Preliminary proxy

Other Filter

Notice of effectiveness

Correspondence with the SEC

Letter from the SEC

Notice of effectiveness

Scanned paper annual report submission